Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Naglaa Hussein

Physical Medicine & Rehabilitation Bronx, NY Medical Doctor

NPI 1942680186 CMS profile 2687551

1181 Grand Concourse, Bronx, NY 10452

Open in the dashboard

General payments

$2,568

144 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Naglaa Hussein of Bronx, NY is reported in the CMS Open Payments database as having received $2,568 across 144 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Physical Medicine & Rehabilitation profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $483 28
2024 General $633 30
2023 General $368 17
2022 General $430 27
2021 General $20 1
2020 General $317 20
2019 General $317 21

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Naglaa Hussein
  • Physical Medicine & Rehabilitation median
  • Middle half of Physical Medicine & Rehabilitation
  • National median

In program year 2025, general payments to Naglaa Hussein were reported at $483. Among 4,146 Physical Medicine & Rehabilitation profiles paid that year, the median was $139 and the middle half received between $48 and $410.

Show as a table
Year Naglaa Hussein Physical Medicine & Rehabilitation median Middle half National median
2019 $317 $133 $45–$390 $163
2020 $317 $88 $29–$272 $114
2021 $20 $116 $33–$360 $132
2022 $430 $123 $40–$378 $149
2023 $368 $131 $43–$396 $160
2024 $633 $141 $45–$409 $164
2025 $483 $139 $48–$410 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Scilex Pharmaceuticals Inc. $2,285 130 payments
  2. Horizon Therapeutics plc $150 8 payments
  3. Intra-Sana Laboratories $76 3 payments
  4. SI-BONE, Inc. $21 1 payment
  5. Phathom Pharmaceuticals, Inc. $18 1 payment
  6. Pfizer Inc. $17 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,568 142 payments
  2. Gift $0 2 payments
Products named General payments · program years 2019–2025
  1. ZTLido $1,817 100 payments
  2. ZTLido 30 POUCH in 1 CARTON 1 PATCH in 1 POUCH $261 18 payments
  3. PENNSAID $150 8 payments
  4. RELTONE 200 MG $76 3 payments
  5. GLYCATE $76 3 payments
  6. RELTONE 400 MG $76 3 payments
  7. ELYXYB - CELECOXIB $50 4 payments
  8. IFUSE IMPLANT $21 1 payment
  9. VOQUEZNA $18 1 payment
  10. EMBEDA $17 1 payment
  11. Other $35 2 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 23 drugs

Part D claims

1,205

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$225,930

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

43.1%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Omeprazole-Sodium Bicarbonate Omeprazole/Sodium Bicarbonate Brand 106 $65,916
Diclofenac Sodium Generic 112 $47,878
Meloxicam Meloxicam, Submicronized Brand 58 $31,129
Ztlido Lidocaine Brand 86 $30,602
Diclofenac Potassium Generic 26 $15,590
Lidocaine Generic 97 $11,795
Naproxen Sodium Er Naproxen Sodium Brand 21 $8,020
Dexlansoprazole Dr Dexlansoprazole Brand 54 $7,562
Cyanocobalamin Injection Cyanocobalamin (Vitamin B-12) Brand 50 $2,330
Pregabalin Generic 26 $1,886

The 10 drugs with the highest cost, of 23 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ZTLido
  • Scilex Pharmaceuticals Inc. $539
$539 86 —
RELTONE 200 MG
  • Intra-Sana Laboratories $25
$25 — —
GLYCATE
  • Intra-Sana Laboratories $25
$25 — —
RELTONE 400 MG
  • Intra-Sana Laboratories $25
$25 — —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $18
$18 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

144 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physical Medicine & Rehabilitation in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record